Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dimesna is the disulfide-linked dimer of mesna (sodium 2-mercaptoethanesulfonate). It is a metabolite formed when two molecules of mesna are oxidized and linked via a disulfide bond. Dimesna itself does not have direct cytoprotective activity but serves as an inactive circulating form that can be reduced back to active mesna in the body. Mesna and its metabolites—including dimesna—are used as uroprotective agents to detoxify harmful metabolites (such as acrolein) produced by chemotherapeutic agents like ifosfamide and cyclophosphamide. The mechanism involves chemical binding to these toxic compounds in the urinary tract, neutralizing their ability to damage bladder tissue[8]. Dimesna is rapidly interconverted with free mesna in plasma through redox reactions[8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on dimesna.